Abstract     Description     Claims     Drawing  

Biochemistry   [0003] 
Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil 2-14C by preneoplastic rat liver and rat hepatoma   [0003] 
Fluorinated pyrimidines, a new class of tumor-inhibitory compounds   [0003] 
a novel agent for the treatment of solid tumors   [0004] 
5-Fluorouracil. Mechanisms of action and clinical strategies   [0004] 
Lancet   [0005] 
The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer   [0005] 
Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies   [0005] 
Fifteen-year trends in metastatic breast cancer survival in Greece   [0005] 
Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer   [0006] 
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer   [0006] 
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group   [0007] 
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus 5-fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study   [0007] 
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11   [0008]  [0009] 
Global cancer statistics   [0009] 
Guidelines 2000 for colon and rectal cancer surgery   [0010] 
Colorectal cancer   [0011] 
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group   [0011] 
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis   [0012] 
5,10-Methylene-5,6,7,8-tetrahydrofolate conformational transitions upon binding to thymidylate synthase: molecular mechanics and continuum solvent studies   [0012] 
Metabolism and mechanism of action of 5-fluorouracil   [0012] 
The impact of folate status on the efficacy of colorectal cancer treatment   [0012] 
Chemical stability and human plasma pharmacokinetics of reduced folates   [0014] 
Phase III Multicenter Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor®/5-Fluorouracil/Bevacizumab Versus Leucovorin/5-Fluorouracil/ Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma Clinical Colorectal   [0015] 
CoFactor: Folate Requirement for Optimization of 5-Fluouracil Activity in Anticancer Chemotherapy   [0015] 
Effects of the diastereoisomers of methylenetetrahydrofolate on the reaction catalyzed by thymidylate synthetase   [0015]  [0064] 
Clin Colorectal Cancer   [0017] 
New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)   [0024] 
Clinical Cancer Research   [0030]  [0064] 
Cancer Chemother Pharmacol   [0034] 
Cancer Res.   [0035] 
Pooled analysis of safety and efficacy of oxaliplatin plus 5-fluorouracil/leucovorin administrated bimonthly in elderly patients with colorectal cancer   [0037] 
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study   [0038] 
Oral uracil and tegafur plus leucovorin compared with iv 5-FU and leucovorin in stage II and III carcinoma of the colon: results from national surgical adjuvant breast and bowel project protocol C-06   [0039] 
Clinical Colorectal Cancer   [0070]